{
  "abstract": "Background Middle meningeal artery embolization (MMAE) is an established treatment for chronic subdural hematoma (CSDH). Current embolic materials achieve permanent arterial occlusion, although the therapeutic target is the inflammatory neovasculature of the outer membrane rather than durable sacrifice of the MMA trunk. Because CSDH activity typically persists for weeks to months before stabilization, temporary inflow suppression during this period may be sufficient to promote membrane stabilization and hematoma resorption. We report a first-in-human evaluation of a biodegradable embolic microsphere designed to provide transient vascular occlusion during the active phase of CSDH.Methods Prospective single-arm pilot feasibility study of symptomatic or enlarging CSDH treated with MMAE using a biodegradable embolic microsphere (NextBiomedical Co., Republic of Korea). Primary endpoints: 30-day procedure-related serious adverse events (SAE), neurological outcome (modified Rankin Scale, mRS), and technical success without catheter occlusion. Secondary endpoints: ≥50% hematoma volume reduction at 8 weeks, avoidance of surgical rescue, and symptom improvement.Results Eight patients underwent embolization. Technical success was achieved in all procedures without catheter obstruction or non-target embolization. No procedure-related SAE or neurological worsening occurred within 30 days, and all patients had stable or improved mRS. Follow-up imaging demonstrated progressive hematoma reduction in all cases, with most achieving ≥50% volume reduction by 8 weeks. No patient required surgical evacuation. Headache and focal symptoms improved during follow-up.Conclusions In this first-in-human experience, MMAE using a biodegradable embolic microsphere showed favorable safety and technical feasibility with encouraging early hematoma resolution. Temporary vascular modulation during the active phase of CSDH may represent a biologically targeted alternative to permanent arterial occlusion. Larger studies are required to determine durability and recurrence rates.Disclosures Y. Kim: 2; C; Medtronic.",
  "authors": [
    {
      "affiliations": [
        "Department of Neurosurgery, Pohang Stroke and Spine Hospital, Pohang-si, Korea, Republic of"
      ],
      "name": "Y Kim"
    },
    {
      "affiliations": [
        "Department of Neurosurgery, Pohang Stroke & Spine Hospital, Pohang-si, Gyeongsangbuk-do, Korea, Republic of"
      ],
      "name": "S Jin"
    }
  ],
  "title": "O-028 First-in-human evaluation of a biodegradable embolic microsphere for middle meningeal artery embolization in chronic subdural hematoma",
  "uid": "f709625a-55eb-5a96-ab45-0810cb9ef546"
}